In order to strengthen the post-marketing surveillance and evaluation of drugs, to ensure drug safety for the public, the State Food and Drug Administration (SFDA), in accordance with the Provisions for Adverse Drug Reaction Reporting and Monitoring, gave a summary and analysis to the national ADR reporting of 2009 and published it as an annual report for the first time.